The anti-fibrotic effects of epigallocatechin-3-gallate in bile duct-ligated cholestatic rats and human hepatic stellate LX-2 cells are mediated by the PI3K/Akt/Smad pathway

Acta Pharmacologica Sinica

Volumn 36, Issue 4, 2015, Pages 473-482

  Yu, Dong Ke ^a,b   Zhang, Cai Xia ^a   Zhao, Shuang Shuang ^a   Zhang, Sheng Hua ^a   Zhang, Hao ^a   Cai, Shi Ying ^c   Shao, Rong Guang ^a   He, Hong Wei ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bile duct ligated rats; cholestasis; epigallocatechin 3 gallate; G3BP1; hepatic stellate cells; liver fibrosis; LY294002; PI3K Akt Smad pathway; TGF 1

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 1 A1; EPIGALLOCATECHIN GALLATE; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMAD2 PROTEIN; SMAD3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CATECHIN; SMAD PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFIBROTIC ACTIVITY; ARTICLE; BILE; BILE DUCT LIGATION; CHOLESTASIS; CONTROLLED STUDY; DRUG ACTIVITY; FIBROGENESIS; GENE EXPRESSION; HEPATITIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER INJURY; LIVER NECROSIS; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SERUM; SIGNAL TRANSDUCTION; STELLATE CELL; URINE; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; BILE DUCT; CELL LINE; COMPLICATION; DRUG EFFECTS; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; BILE DUCTS; CATECHIN; CELL LINE; CHOLESTASIS; HEPATIC STELLATE CELLS; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SMAD PROTEINS;

EID: 84926349265     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2014.155     Document Type: Article

References (20)

1. Friedman SL. Hepatic fibrosis - overview. Toxicology 2008; 254: 120-9.
2. Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol 2013; 3: 1473-92.
3. Hirschfield GM, Heathcote EJ, Gershwin ME. Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology 2010; 139: 1481-96.
4. Fickert P, Stieger B. Molecular pathogenesis of chronic cholestatic liver disease: Impact on novel therapeutic approaches. Mol Aspects Med 2014; 37: 1-2.
5. Shanafelt TD, Call TG, Zent CS, Leis JF, LaPlant B, Bowen DA, et al. Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer 2013; 119: 363-70.
6. Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 2011; 82: 1807-21.
7. Yasuda Y, Shimizu M, Sakai H, Iwasa J, Kubota M, Adachi S, et al. (-)-Epigallocatechin gallate prevents carbon tetrachloride-induced rat hepatic fibrosis by inhibiting the expression of the PDGFRbeta and IGF-1R. Chem Biol Interact 2009; 182: 159-64.
8. Tipoe GL, Leung TM, Liong EC, Lau TY, Fung ML, Nanji AA. Epigallocatechin-3-gallate (EGCG) reduces liver inflammation, oxidative stress and fibrosis in carbon tetrachloride (CCl4)-induced liver injury in mice. Toxicology 2010; 273: 45-52.
9. Xiao J, Ho CT, Liong EC, Nanji AA, Leung TM, Lau TY, et al. Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways. Eur J Nutr 2014; 53: 187-99.
10. Sakata R, Ueno T, Nakamura T, Sakamoto M, Torimura T, Sata M. Green tea polyphenol epigallocatechin-3-gallate inhibits platelet-derived growth factor-induced proliferation of human hepatic stellate cell line LI90. J Hepatol 2004; 40: 52-9.
11. Higashi N, Kohjima M, Fukushima M, Ohta S, Kotoh K, Enjoji M, et al. Epigallocatechin-3-gallate, a green-tea polyphenol, suppresses Rho signaling in TWNT-4 human hepatic stellate cells. J Lab Clin Med 2005; 145: 316-22.
12. Nakamuta M, Higashi N, Kohjima M, Fukushima M, Ohta S, Kotoh K, et al. Epigallocatechin-3-gallate, a polyphenol component of green tea, suppresses both collagen production and collagenase activity in hepatic stellate cells. Int J Mol Med 2005; 16: 677-81.
13. Yumei F, Zhou Y, Zheng S, Chen A. The antifibrogenic effect of (-)-epigallocatechin gallate results from the induction of de novo synthesis of glutathione in passaged rat hepatic stellate cells. Lab Invest 2006; 86: 697-709.
14. Zhen MC, Huang XH, Wang Q, Sun K, Liu YJ, Li W, et al. Green tea polyphenol epigallocatechin-3-gallate suppresses rat hepatic stellate cell invasion by inhibition of MMP-2 expression and its activation. Acta Pharmacol Sin 2006; 27: 1600-7.
15. Shim JH, Su ZY, Chae JI, Kim DJ, Zhu F, Ma WY, et al. Epigallocatechin gallate suppresses lung cancer cell growth through Ras-GTPase-activating protein SH3 domain-binding protein 1. Cancer Prev Res (Phila) 2010; 3: 670-9.
16. He H, Mennone A, Boyer JL, Cai SY. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology 2011; 53: 548-57.
17. Fickert P, Fuchsbichler A, Marschall HU, Wagner M, Zollner G, Krause R, et al. Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am J Pathol 2006; 168: 410-22.
18. Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, Blaner WS, et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 2005; 54: 142-51.
19. Zhang H, Zhang S, He H, Zhao W, Chen J, Shao RG. GAP161 targets and downregulates G3BP to suppress cell growth and potentiate cisplaitin-mediated cytotoxicity to colon carcinoma HCT116 cells. Cancer Sci 2012; 103: 1848-56.
20. Maillette de Buy Wenniger L, Beuers U. Bile salts and cholestasis. Dig Liver Dis 2010; 42: 409-18.